Multiple Myeloma and Fatty Acid Metabolism
ABSTRACT Multiple myeloma (MM) accounts for 13% to 15% of all blood cancers and is characterized by the proliferation of malignant cells within the bone marrow (BM). Despite important advances in treatment, most patients become refractory and relapse with the disease. As MM tumors grow in the BM, th...
Main Authors: | Majdi Masarwi, Abigail DeSchiffart, Justin Ham, Michaela R. Reagan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-03-01
|
Series: | JBMR Plus |
Subjects: | |
Online Access: | https://doi.org/10.1002/jbm4.10173 |
Similar Items
-
Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group
by: Jelena Bila, et al.
Published: (2021-08-01) -
Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications
by: Jacqueline Schütt, et al.
Published: (2021-08-01) -
Boosting Immunity against Multiple Myeloma
by: Raquel Lopes, et al.
Published: (2021-03-01) -
Therapeutic Irradiation: Consequences for Bone and Bone Marrow Adipose Tissue
by: Samantha Costa, et al.
Published: (2019-08-01) -
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
by: Chia-Hung Yen, et al.
Published: (2018-11-01)